Evidence map›Paper›PMID 26628371›Full record

ArticleCell reports2015

Methylome-wide Sequencing Detects DNA Hypermethylation Distinguishing Indolent from Aggressive Prostate Cancer.

Jeffrey M Bhasin, Byron H Lee, Lars Matkin, Margaret G Taylor, Bo Hu, Yaomin Xu, Cristina Magi-Galluzzi, Eric A Klein, Angela H Ting

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Epigenetic (De)regulation in Prostate Cancer.Cancer treatment and research · 2023
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jeffrey M BhasinDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Byron H LeeGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Lars MatkinGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Margaret G TaylorGenomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Bo HuQuantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Yaomin XuDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN 37240, USA.
Cristina Magi-GalluzziRobert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Angela H TingDepartment of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: tinga@ccf.org.

Funding

Characterizing the DNA methylomes of indolent and aggressive prostate cancersR01CA154356 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI TING, ANGELA H · 2011 to 2015
$1.6M
The function of differential DNA methylation in aggressive prostate cancerF31CA195887 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI BHASIN, JEFFREY M · 2015 to 2016
$56k
Howard Hughes Medical InstituteNCI NIH HHS F31 CA195887NCI NIH HHS F31CA195887NCI NIH HHS R01 CA154356NCI NIH HHS R01CA154356
6 · The paper itself

Abstract

A critical need in understanding the biology of prostate cancer is characterizing the molecular differences between indolent and aggressive cases. Because DNA methylation can capture the regulatory state of tumors, we analyzed differential methylation patterns genome-wide among benign prostatic tissue and low-grade and high-grade prostate cancer and found extensive, focal hypermethylation regions unique to high-grade disease. These hypermethylation regions occurred not only in the promoters of genes but also in gene bodies and at intergenic regions that are enriched for DNA-protein binding sites. Integration with existing RNA-sequencing (RNA-seq) and survival data revealed regions where DNA methylation correlates with reduced gene expression associated with poor outcome. Regions specific to aggressive disease are proximal to genes with distinct functions from regions shared by indolent and aggressive disease. Our compendium of methylation changes reveals crucial molecular distinctions between indolent and aggressive prostate cancer.

Indexed as

CpG IslandsDNA, IntergenicDNA MethylationGenome-Wide Association StudyHumansMaleOligonucleotide Array Sequence AnalysisPrincipal Component AnalysisPromoter Regions, GeneticProstatic NeoplasmsDNA, Intergenic

Identifiers

PMID26628371
PMCPMC4684962

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.